Daiichi Sankyo Company has launched the Immune-mediated Inflammatory Diseases Consortium for Drug Development to research and discover drugs for intractable immune-mediated inflammatory diseases.
The consortium has been launched in collaboration with Keio University; Kochi University; the National Institutes of Biomedical Innovation, Health and Nutrition; Ono Pharmaceutical Co., and Mitsubishi Tanabe Pharma Corporation.
With the aim of curing intractable immune-mediated inflammatory diseases, reverse translational research for drug discovery research is being conducted worldwide using data on clinical samples analysed with the latest technologies.
However, as the number of clinical samples from patients with intractable immune-mediated inflammatory diseases is limited, and the increasing costs of drug discovery are burdensome, Daiichi has established this organisation to efficiently discover drugs through collaboration among multiple academia and industry members.
In the consortium, the Department of Rheumatology and Department of Gastroenterology and Hepatology, Keio University Hospital, and the Centre for Intractable Immune Disease, Kochi Medical School, Kochi University will collect samples and detailed clinical information before and after treatment as an inception cohort from the patients with multiple intractable immune-mediated inflammatory diseases.
These samples from the patients will be examined at the National Institutes of Biomedical Innovation, Health and Nutrition through detailed and comprehensive analysis, including transcriptome analysis.
A high-quality database, consisting of various types of data accumulated in the consortium, will be shared among the participating academia members and pharmaceutical companies.
While each pharmaceutical company conducts original drug discovery research for intractable immune-mediated inflammatory diseases utilizing this database, each academia member will utilize the study outcomes for further basic research and applied research.
The consortium will thus function based on this unprecedented concept of industry-academia collaboration.